The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy and safety of LM-302 (anti-claudin 18.2 ADC) in combination with anti-PD-1 therapy for advanced gastric, gastroesophageal junction cancer and esophageal adenocarcinoma: Early-phase study results.
 
Haiping Jiang
No Relationships to Disclose
 
Mingzhu Huang
No Relationships to Disclose
 
Lixin Wan
No Relationships to Disclose
 
Ben Markman
Consulting or Advisory Role - AstraZeneca; Greywolf Therapeutics
 
Hongming Pan
No Relationships to Disclose
 
Chunmei Bai
No Relationships to Disclose
 
Aiping Zhou
No Relationships to Disclose
 
Yiping Mou
No Relationships to Disclose
 
Xiang-lin Yuan
No Relationships to Disclose
 
Linbin Dou
Employment - LaNova Medicines Limited
 
Zhihua Gong
Employment - LaNova Medicines Limited
 
Da Fei
Employment - LaNova Medicines Limited
 
Xia Qin
Employment - LaNova Medicines Limited
 
Crystal Qin
Employment - LaNova Medicines Limited
Leadership - LaNova Medicines Limited
 
Jin Li
No Relationships to Disclose